Lenka Bauerová

Lenka Bauerová

Auto-generated profile, based on publicly available information

Lenka Bauerová

Department of Pathology, First Faculty of Medicine Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2013 in Cor et Vasa
Verified
Journal Article
Closed access
MFMichal Fikrle
Michal Fikrle
TPTomáš Paleček
Tomáš Paleček
PKPetr Kuchynka
Petr Kuchynka
ENEduard Němeček
Eduard Němeček
LBLenka Bauerová
Lenka Bauerová
RRRomana Ryšavá
Romana Ryšavá
Cardiac amyloidosis is characterized by clinically significant extracellular amyloid infiltration of the heart that is usually, but not always, associated with the involvement of other organs depending on the type of amyloid. Cardiac involvement represents the most important prognostic factor especially in AL amyloidosis and thus early diagnosis of amyloid heart disease is of utmost importance influencing further management of the patients. This review aims to broadly discuss pathogenesis, manifestation and complex diagnostics of amyloidosis with the main focus on amyloid cardiomyopathy. Also, the summary of current therapeutic options that have great potential to improve existing poor prognosis of affected individuals is given

1 November 2012 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
THTomáš Honzík
Tomáš Honzík
MMMartin Magner
Martin Magner
JKJakub Krijt
Jakub Krijt
JSJitka Sokolová
Jitka Sokolová
OVOliver Vugrek
Oliver Vugrek
VKViktor Kožich
Viktor Kožich

2 September 2011 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
PDF file
DMDita Maixnerova
Dita Maixnerova
LBLenka Bauerova
Lenka Bauerova
JSJelena Skibova
Jelena Skibova
RRRomana Rysava
Romana Rysava
JRJana Reiterova
Jana Reiterova
VTVladimir Tesar
Vladimir Tesar
Background. The aim of our study was to retrospectively analyse the clinical data and the histological findings of 343 patients (pts) followed up with IgA nephropathy (IgAN) in our department of nephrology. We have assessed the main demographic, clinical and histological data, and the medical treatment of IgAN pts. Methods. Multivariate analysis was used to evaluate the effect of different variables on ≥ 50% increase of plasma creatinine level from baseline during a median follow-up of 4 years. Results. In our group of IgAN pts, the male gender (68%) predominated over female gender (32%). At the time of renal biopsy, the median age of IgAN pts was 32.3 (18–90) years, the median level of serum creatinine was 119 μmol/L and the median level of proteinuria was 1.8 g/day. Most of the pts were found to have arterial hypertension (56.7%). The majority of the pts with arterial hypertension were treated with inhibitors of angiotensin-converting enzyme (80.4%) and the remaining pts (42.6%) were treated with angiotensin II receptor blockers. Fifty per cent of the pts (170 pts) were treated of corticosteroids, 21% of the pts (71 pts) used a combined immunosuppressive treatment of corticosteroids and cyclophosphamide, 8% of the pts (27 pts) took azathioprine, 1.5% of the pts (5 pts) took cyclosporine and 1.5% of the pts (5 pts) were given mycophenolate mofetil. Hypertension at presentation, fibrointimal proliferation of arterial vessels, interstitial fibrosis and interstitial inflammation were shown to be associated with ≥50% increase of plasma creatinine level from baseline in univariate analysis (P < 0.05 for hypertension and fibrointimal proliferation; P < 0.01 for interstitial fibrosis and inflammation). Using stepwise logistic regression presenting proteinuria >2 g/day [odds ratio (OR) = 2.24, P < 0.01], tubular atrophy (OR = 4.97, P < 0.01) and damage of tubular epithelium (OR = 1.78, P < 0.05) were found as risk factors for ≥50% increase of plasma creatinine level from baseline. Conclusion. Our retrospective analysis found valuable information not only about the clinical, laboratory and histological findings in IgAN pts but also information about the risk factors influencing the progression of renal insufficiency.

3 January 2017 in Pathology and Oncology Research
Verified
Journal Article
Closed access
PDF file
PDPavel Dundr
Pavel Dundr
KNKristyna Nemejcova
Kristyna Nemejcova
JLJan Laco
Jan Laco
HSHelena Skálová
Helena Skálová
LBLenka Bauerová
Lenka Bauerová
DFDaniela Fischerova
Daniela Fischerova

5 March 2010 in Pathology and Oncology Research
Verified
Journal Article
Closed access
PDF file
PDPavel Dundr
Pavel Dundr
DFDaniela Fischerova
Daniela Fischerova
CPCtibor Povýšil
Ctibor Povýšil
ABAdéla Berková
Adéla Berková
LBLenka Bauerová
Lenka Bauerová
DCDavid Cibula
David Cibula

3 December 2014 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
TPTomas Palecek
Tomas Palecek
MFMichal Fikrle
Michal Fikrle
ENEduard Nemecek
Eduard Nemecek
LBLenka Bauerova
Lenka Bauerova
PKPetr Kuchynka
Petr Kuchynka
RRRomana Rysava
Romana Rysava
The amyloidoses represent a group of diseases characterized by extracellular deposition of abnormal protein, amyloid, which is formed by insoluble extracellular fibrils in β-pleated sheets. Although cardiac involvement may occur in all types of amyloidoses, clinically relevant amyloid cardiomyopathy is a typical feature of AL amyloidosis and transthyretin-related amyloidoses. Congestive heart failure represents the commonest manifestation of amyloid heart disease. Noninvasive imaging techniques, especially echocardiography and cardiac magnetic resonance, play a major role in the diagnosis of amyloid cardiomyopathy; however, histological confirmation and exact typing of amyloid deposits is necessary whether in extracardiac location or directly in the myocardium. Early diagnosis of amyloid heart disease is of utmost importance as the presence and especially the severity of cardiac involvement generally drives the prognosis of affected subjects and plays a major role in determining the intensity of specific treatment, namely in AL amyloidosis. The management of patients with amyloid heart disease is complex. Loop diuretics together with aldosterone antagonists represent the basis for influencing signs of congestion. In AL amyloidosis, high-dose chemotherapy followed by autologous stem cell transplantation is generally considered to be a front-line treatment option, if the disease is diagnosed at its early stage. The combination of mephalan with dexamethasone has been the standard therapy for severely affected individuals; however, the combinations with several novel agents including immunomodulatory drugs and bortezomibe have been tested in clinical trials with promising results. New therapeutic substances with the potential to slow or even stop the progression of transthyretin-related amyloidosis are also extensively studied.